Several approaches to inhibiting tumour angiogenesis by targeting VEGF signalling have been developed (3–6) and are currently approved for use in the clinic against a number of tumour types including colorectal (3), renal (5), glioblastoma (7), hepatocellular (8) and lung (9). This evidence concerns the gene VEGFA and neoplasm.